The 10K (Annual Report) is out. If nothing else, they are at least filing robust reports nowadays. No, we never get to talk to the CEO to ask questions, but at least the info exists. My takeaway from skimming it is that they are serious about re-entering the equity markets, they are ready to initiate the first two clinical trials, and they plan to build a second manufacturing facility. I don't think they have the funding to do that last one this year. It seems to me that they probably have the cash to do the clinical trials or the new facility, but not both. But who knows.
So, yeah, I think this is finally the year that the logjam breaks, on multiple fronts. That doesn't mean the results will be good. It could be the year that the equity officially becomes worthless. Or, who knows, the shares could be trading at $30 this fall with some favorable buzz. But I do think we'll finally be out of the black hole we entered in 2020.
